{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:03:49Z","timestamp":1768863829921,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/deed.de"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00292-025-01500-3","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:14:23Z","timestamp":1763990063000},"page":"68-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Zervixkarzinomscreening in Deutschland 2020\u20132022","Cervical cancer screening in Germany 2020\u20132022"],"prefix":"10.1007","volume":"47","author":[{"given":"Birgit","family":"P\u00f6schel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus J.","family":"Neis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"3","key":"1500_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray\u00a0F et\u00a0al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263","journal-title":"CA Cancer J Clin"},{"key":"1500_CR2","unstructured":"IARC. Cancer Today IARC.pdf. Incidence, Both sexes, in 2022 2022 [cited 2022 27.10.2022]; Available from: iarc.fr."},{"key":"1500_CR3","unstructured":"Bundesausschuss KLG (2018) Zervixkarzinomscreening. https:\/\/www.g-ba.de\/downloads\/40-268-6040\/2018-11-22_oKFE-RL_Zervixkarzinom_IQTIG-Konzept.pdf. Zugegriffen: 14. Febr. 2025"},{"key":"1500_CR4","unstructured":"Robert-Koch-Institut (2016) Bericht zum Krebsgeschehen in Deutschland 2016. Epidemiologie von Krebserkrankungen Geb\u00e4rmutterhalskrebs. https:\/\/edoc.rki.de\/bitstream\/handle\/176904\/3264\/28oaKVmif0wDk.pdf?sequence=1&isAllowed=y. Zugegriffen: 14. Febr. 2025"},{"issue":"2","key":"1500_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","volume":"384","author":"H zur Hausen","year":"2009","unstructured":"zur Hausen\u00a0H (2009) Papillomaviruses in the causation of human cancers\u2014a\u00a0brief historical account. Virology 384(2):260\u2013265","journal-title":"Virology"},{"issue":"4","key":"1500_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ijc.27713","volume":"132","author":"WA Tjalma","year":"2013","unstructured":"Tjalma\u00a0WA et\u00a0al (2013) Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer 132(4):854\u2013867","journal-title":"Int J Cancer"},{"issue":"1","key":"1500_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/LGT.0000000000000494","volume":"24","author":"JH Bonde","year":"2020","unstructured":"Bonde\u00a0JH et\u00a0al (2020) Clinical Utility of Human Papillomavirus Genotyping in Cervical Cancer Screening: A\u00a0Systematic Review. J\u00a0Low Genit Tract Dis 24(1):1\u201313","journal-title":"J Low Genit Tract Dis"},{"key":"1500_CR8","doi-asserted-by":"crossref","unstructured":"Rayner M et\u00a0al (2023) Cervical Cancer Screening Recommendations: Now and for the Future. Healthc (basel) 11(16)","DOI":"10.3390\/healthcare11162273"},{"issue":"4","key":"1500_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1158\/1055-9965.EPI-12-1406","volume":"22","author":"M Schiffman","year":"2013","unstructured":"Schiffman\u00a0M, Wentzensen\u00a0N (2013) Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 22(4):553\u2013560","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"(6): p","key":"1500_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00292-011-1475-6","volume":"32","author":"N Wentzensen","year":"2011","unstructured":"Wentzensen\u00a0N (2011) Molecular diagnosis of HPV infections. Pathologe 32((6): p):461\u2013466","journal-title":"Pathologe"},{"key":"1500_CR11","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (2024) Vereinbarung von Qualit\u00e4tssicherungsma\u00dfnahmen nach \u00a7\u00a0135 Abs.\u00a02 SGB\u00a0V. https:\/\/www.kbv.de\/media\/sp\/Zervix-Zytologie.pdf. Zugegriffen: 14. Febr. 2025"},{"issue":"10","key":"1500_CR12","first-page":"1235","volume":"83","author":"U Schenck","year":"2023","unstructured":"Schenck\u00a0U et\u00a0al (2023) Evaluations of the 2019 Annual Statistics Under the Cervical Cytology Quality Assurance Agreement. 2019 Annu Stat Cerv Cytol From 15608413 Women Geburtshilfe Frauenheilkd 83(10):1235\u20131249","journal-title":"2019 Annu Stat Cerv Cytol From 15608413 Women Geburtshilfe Frauenheilkd"},{"issue":"1","key":"1500_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1186\/s12879-024-09827-7","volume":"24","author":"LA Liang","year":"2024","unstructured":"Liang\u00a0LA et\u00a0al (2024) Population-based age- and type-specific prevalence of human papillomavirus among non-vaccinated women aged 30\u00a0years and above in Germany. BMC Infect Dis 24(1):1008","journal-title":"BMC Infect Dis"},{"issue":"12","key":"1500_CR14","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1055\/a-1886-3311","volume":"82","author":"A Xhaja","year":"2022","unstructured":"Xhaja\u00a0A et\u00a0al (2022) Two Years of Cytology and HPV Co-Testing in Germany: Initial Experience. Geburtshilfe Frauenheilkd 82(12):1378\u20131386","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1500_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00129-022-05014-4","volume":"55","author":"K Marquardt","year":"2022","unstructured":"Marquardt\u00a0K, Ziemke\u00a0P (2022) Co-test in cervical cancer screening: the first round. Die Gyn\u00e4kologie 55:867\u2013874","journal-title":"Die Gyn\u00e4kologie"},{"issue":"11","key":"1500_CR16","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1158\/1055-9965.EPI-19-0239","volume":"28","author":"R Adcock","year":"2019","unstructured":"Adcock\u00a0R et\u00a0al (2019) Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia. Cancer Epidemiol Biomarkers Prev 28(11):1816\u20131824","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"e86835","key":"1500_CR17","first-page":"1","volume":"9","author":"M Rebolj","year":"2014","unstructured":"Rebolj\u00a0M et\u00a0al (2014) Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening. Plos One 9(e86835):1","journal-title":"Plos One"},{"key":"1500_CR18","unstructured":"Gesundheitsforen Leipzig Gmb H, Zervixkarzinom E (2024) from. https:\/\/www.g-ba.de\/downloads\/17-98-5680\/2024-04-24_oKFE-Evaluationsbericht-Gebaermutterhalskrebs_GFL_2021-2022.pdf. Zugegriffen: 14. Febr. 2025"},{"issue":"10","key":"1500_CR19","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1055\/a-2159-7510","volume":"83","author":"M Henes","year":"2023","unstructured":"Henes\u00a0M et\u00a0al (2023) Registry Study of the Working Group on Cervical Pathology and Colposcopy (AGCPC) on the Diagnostic Algorithm for the New Cervical Cancer Screening\u2014Initial Data. Geburtshilfe Frauenheilkd 83(10):1250\u20131262","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"1500_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s00404-022-06747-2","volume":"p","author":"F Neis","year":"2022","unstructured":"Neis\u00a0F et\u00a0al (2022) Proposal for a\u00a0descriptive and differentiated presentation of the longitudinal impact of the new organized cancer screening guideline and HPV vaccination in Germany. Arch Gynecol Obstet p:1125\u20131136","journal-title":"Arch Gynecol Obstet"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01500-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01500-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:57:18Z","timestamp":1768816638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01500-3"}},"subtitle":["Eine Analyse der ersten Screeningrunde nach den Vorgaben der oKFE-RL","An analysis of the first round of screening according to the specifications of the oKFE-RL"],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":20,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01500-3","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0P\u00f6schel und K.J.\u00a0Neis geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Hierzu liegt das Votum der Ethikkommissionen Mecklenburg-Vorpommerns vor (BB 121\/22). F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}